Cefodizime

Parenteral
Lower respiratory tract infections, Urinary tract infections

Parenteral
Gonorrhoea

Parenteral:
Lower respiratory tract infections, Urinary tract infections: In patients undergoing dialysis: 0.5-1 g daily is given after dialysis.

CrCl (mL/min)	Dosage
<10	0.5-1 g daily.
10-30	1-2 g daily.

Gonorrhoea: Dose adjustment may be needed.

Hypersensitivity to cephalosporins.

Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.

Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; pseudomembranous colitis; hepatic dysfunction; haematologic disorders; pain at inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.

Renal clearance reduced by probenecid.

Positive direct antiglobulin Coombs' test; falsely high values with Jaffe method of measuring creatinine concentrations; positive reactions for false glucose using copper-reduction reactions; transient increases in liver enzyme values.

Description:
Mechanism of Action: Cefodizime has uses similar to cefotaxime, but without active metabolite. It has variable activity against Citrobacter spp., and P. aeruginosa and B. fragilis are generally resistant.
Pharmacokinetics:
Distribution: About 80% bound to plasma proteins. Widely distributed into body tissues and fluids. Crosses the placenta and detected in breast milk.
Excretion: Terminal elimination half-life of about 4 hr. Mainly excreted unchanged in the urine.

Cephalosporin